Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects

被引:112
|
作者
Doose, DR
Wang, SS
Padmanabhan, M
Schwabe, S
Jacobs, D
Bialer, T
机构
[1] Hebrew Univ Jerusalem, Dept Pharmaceut, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel
[3] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
关键词
topiramate; carbamazepine; ethinyl estradiol; norethidrone; obesity;
D O I
10.1046/j.1528-1157.2003.55602.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: To study the pharmacokinetics of a combination oral contraceptive (OC) containing norethindrone and ethinyl estradiol during OC monotherapy, concomitant OC and topiramate (TPM) therapy, and concomitant OC and carbamazepine (CBZ) therapy in order to comparatively evaluate the pharmacokinetic interaction, which may cause contraceptive failure. Methods: This randomized, open-label, five-group study included two 28-day cycles. Five groups of female subjects received oral doses of ORTHO-NOVUM 1/35 alone (cycle 1) and then concomitant with TPM or CBZ (cycle 2). The treatment groups were group 1, TPM, 50 mg/day; group 2, TPM, 100 mg/day; group 3, TPM, 200 mg/day; group 4, TPM, 200 mg/day (obese women); and group 5, CBZ, 600 mg/day. Group 4 comprised obese women whose body mass index (BMI) was between 30 and 35 kg/m(2). The BMI of the remaining four groups was less than or equal to27 kg/m(2). Results: Coadministration of TPM at daily doses of 50, 100, and 200 mg (nonobese) and 200 mg (obese) nonsignificantly (p > 0.05) changed the mean area under the curve (AUC) of ethinyl estradiol by -12%, +5%, -11%, and -9%, respectively, compared with OC monotherapy. A similar nonsignificant difference was observed with the plasma levels and AUC values of norethindrone (p > 0.05). CBZ (600 mg/day) significantly (p < 0.05) decreased the AUC values of norethindrone and ethinyl estradiol by 58% and 42%, respectively, and increased their respective oral clearance by 69% and 127% (p < 0.05). Because CBZ induces CYP 3A-mediated and glucuronide conjugation metabolic pathways, the significant increase in the oral clearance of ethinyl estradiol and norethindrone was anticipated. Conclusions: TPM, at daily doses of 50-200 mg, does not interact with an OC containing norethindrone and ethinyl estradiol. The lack of the TPM-OC interaction is notable when it is compared with the CBZ-OC interaction.
引用
收藏
页码:540 / 549
页数:10
相关论文
共 50 条
  • [41] Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life
    Borenstein, J
    Yu, HT
    Wade, S
    Chiou, CF
    Rapkin, A
    JOURNAL OF REPRODUCTIVE MEDICINE, 2003, 48 (02) : 79 - 85
  • [42] Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 μg of ethinyl estradiol
    Paoletti, AM
    Lello, S
    Fratta, S
    Orrù, M
    Ranuzzi, F
    Sogliano, C
    Concas, A
    Biggio, G
    Melis, GB
    FERTILITY AND STERILITY, 2004, 81 (03) : 645 - 651
  • [43] Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women
    Anderson, Matt S.
    Hanley, William D.
    Moreau, Allison R.
    Jin, Bo
    Bieberdorf, Frederick A.
    Kost, James T.
    Wenning, Larissa A.
    Stone, Julie A.
    Wagner, John A.
    Iwamoto, Marian
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (04) : 616 - 620
  • [44] A PHASE I, OPEN-LABEL STUDY TO DETERMINE THE EFFECT OF SYM-1219 ON THE PHARMACOKINETICS OF ETHINYL ESTRADIOL (EE2) AND NORETHINDRONE (NET) IN HEALTHY FEMALE VOLUNTEERS.
    Pentikis, H. S.
    Adetoro, N.
    Braun, C. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S87 - S88
  • [45] Absence of Clinically Significant Drug Interactions with Co-administration of Atogepant and an Ethinyl Estradiol-Levonorgestrel Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis
    Ankrom, W.
    Xu, J.
    Vallee, M.
    Dockendorf, M. F.
    Armas, D.
    Boinpally, R.
    Min, K.
    HEADACHE, 2019, 59 : 89 - 89
  • [46] Absence of Clinically Significant Drug Interactions With Co-administration of Atogepant and an Ethinyl Estradiol-Levonorgestrel Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis
    Ankrom, Wendy
    Xu, Jialin
    Vallee, Marie-Helene
    Dockendorf, Marissa F.
    Armas, Danielle
    Boinpally, Ramesh
    Min, K. Chris
    CEPHALALGIA, 2019, 39 : 33 - 33
  • [47] EFFECTS OF AN ORAL-CONTRACEPTIVE COMBINATION CONTAINING 0.150 MG DESOGESTREL PLUS 0.020 MG ETHINYL ESTRADIOL ON HEALTHY PREMENOPAUSAL WOMEN
    DEALOYSIO, D
    MAULONI, M
    RONCUZZI, A
    ALTIERI, P
    BOTTIGLIONI, F
    TROSSARELLI, GF
    FANIZZA, G
    COVELLI, A
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993, 253 (01) : 15 - 19
  • [48] Effect of the Hepatitis C Virus Protease Inhibitor Faldaprevir on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers
    Sabo, John P.
    Lang, Benjamin
    Elgadi, Mabrouk
    Huang, Fenglei
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (01) : 514 - 519
  • [49] NO ADVERSE IMPACT OF REPEATED ORAL DOSES OF TERIFLUNOMIDE ON THE PHARMACOKINETICS OF ORAL CONTRACEPTIVE STEROIDS (ETHINYLESTRADIOL AND LEVONORGESTREL) IN YOUNG HEALTHY FEMALE SUBJECTS
    Turpault, S.
    Miller, B.
    Menguy-Vacheron, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S29 - S30
  • [50] Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: A double-blind, placebo-controlled study
    Taekema-Roelvink, MEJ
    Swart, PJ
    Kuipers, ME
    Krauwinkel, WJJ
    Visser, N
    Smulders, RA
    CLINICAL THERAPEUTICS, 2005, 27 (09) : 1403 - 1410